Advanced Pancreatic Cancer - prIME Oncology
prIME Decision Points
prIME Decision Points

Advanced Pancreatic Cancer

Selecting Best Strategies to Optimize Patient Outcomes

View Activity

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Hear from the experts about the best strategies to optimize patient outcomes in advanced pancreatic cancer, which include optimizing the continuum-of-care approach and fine-tuning systemic therapy in pancreatic cancer. A clinical scenario with patient history, laboratory results, and options for next steps in treatment provide commentary and insight for decision making in the care of your patients with advanced pancreatic cancer.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



Release Date

Release Date

Mar 13, 2018

Expiration Date

Mar 13, 2019

Case 1: Optimizing the continuum-of-care approach in advanced pancreatic cancer

  • Clinical case
  • First-line therapy
  • Second-line therapy
  • Managing adverse events of nal-IRI+5FU/LV
  • prIME Points™

Case 2: Fine-tuning systemic therapy in advanced pancreatic cancer

  • Clinical case
  • Molecular testing in mPCA
  • Recurrent MSS PCA
  • Recurrent MSI-H PCA
  • BRCA-associated mpCA
  • prIME Points™
  • Philip Agop Philip, MD, PhD, FRCPWayne State University and Karmanos Cancer Institute
    Detroit, Michigan, United States
  • Thomas Seufferlein, MD, PhD University of Ulm
    Ulm, Germany

This educational activity is designed for medical oncologists, gastroenterologists, and other healthcare providers involved in the management of patients with pancreatic cancer.

After completion of this educational activity, participants should be able to:

  • Assess factors that impact treatment decision making in metastatic pancreatic adenocarcinoma
  • Select an optimal treatment sequences for individual patients with metastatic pancreatic cancer
  • Compare and contrast second-line treatment options for progressive metastatic pancreatic cancer
  • Explain adverse events associated with chemotherapy regimens used in metastatic pancreatic cancer and identify treatment strategies

This educational activity is supported by a grant from Shire.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This activity is provided by prIME Oncology.

Disclosure Information


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.